The Enhanced Medication Therapy Management (MTM) model is an opportunity for Part D basic stand-alone prescription drug plans (PDPs) to offer innovative MTM programs aimed at improving quality of care while also reducing costs. The Enhanced MTM model seeks to determine whether providing Part D sponsors with additional payment incentives and MTM regulatory flexibilities achieves the key goals of MTM—optimized therapeutic outcomes through improved medication use, and reduced risk of adverse events (including adverse drug interactions)—while reducing net Medicare expenditures. In addition to enhanced MTM encounter data elements, this document presents three monitoring measures CMS will use to assess the Enhanced MTM model. Although monitoring measures will not be used to determine Part D sponsors’ eligibility for performance-based payments under the model, CMS wishes to pilot monitoring measures that will be calculated uniformly for all model participants using sponsor-submitted enhanced MTM encounter and Medicare claims data.